Pupillometry responses may serve as biomarkers for depression, provide treatment indications

News
Article

The findings come from a collaborative study between investigators at the Max Planck Institute of Psychiatry, Munich and the Department of Cognitive Sciences, University of California, Irvine

A woman sits in a dark room, looking sadly at the floor.

The study authors pointed out the current absence of biomarkers for major depressive disorder. Image credit: ©StockPhotoPro – stock.adobe.com

A collaborative study between investigators at the Max Planck Institute of Psychiatry, Munich, Germany, and the Department of Cognitive Sciences, University of California, Irvine, United States, found that the usefulness of pupillometry as a clinical test may lie in its ability to identify a specific subgroup of patients with anticipatory hypo-arousal subserving anhedonia symptomatology,1 which may serve as a biomarker of depression.

Led by Andy Brendler, a researcher at the Max Planck Institute of Psychiatry, the group of authors pointed out the current absence of biomarkers for major depressive disorder.

In their study, the investigators analysed a replication sample of 40 unmedicated patients diagnosed with depression that was not treated and 30 healthy controls. The participants performed a reward anticipation task during which their pupillary responses were measured.

Dr Brendler and associates explained that there has been recent interest in the pupillary response, some of which includes the following studies.“The pupillary light reflex, which is an index of pupil size in response to light, characterised by an immediate constriction followed by a dilation,2 is altered in depression. It was observed that patients with a MDD diagnosis had an attenuated constriction velocity3 and an overall lower constriction change4-6 of the pupil in response to light stimuli relative to control participants,” the authors reported.

Findings associated with changes in pupillometry responses

The investigators identified a negative correlation between pupillary dilation and symptom load during reward anticipation in patients diagnosed with major depressive disorder. When the study data were analysed from all 136 participants (ie, 81 unmedicated depressed and 55 healthy control participants), the investigators reported that “reduced pupil dilation in anticipation of reward is inversely associated with anhedonia items of the Beck Depression Inventory in particular.”

In addition, functional magnetic resonance imaging performed simultaneously showed that the right anterior insula as part of the salience network was negatively correlated with depressive symptom load in general and anhedonia items specifically.

This may provide valuable information for treatment allocation and examining the early treatment response. The finding of less pupillary response in patients with depression has implications in treatment.

“Considering that an estimated 30% of depressive patients do not improve using the currently available medications, understanding the physiological mechanisms behind depression and fine-tuning diagnosis and treatment accordingly [are] urgently required,” the authors said.

In discussing their findings, the investigators expressed confidence that the anticipatory hypo-arousal identified by pupillometry is correlated with the depressive symptom load in patients with major depressive disorder. They also believe the study provided “evidence that certain depressed patients can be characterised by anticipatory hypo-arousal assessed by decreased pupil dilation during reward anticipation, with specificity for anhedonia and lack of energy-related items.”

This led them to conclude that pupillometry has value as a clinical test to identify a specific subgroup of patients with anticipatory hypo-arousal subserving anhedonia symptomatology. In addition, this may be valuable when considering treatments in individual patients.

References

  1. Brendler A, Schneider M, Elbau IG, et al. Assessing hypo-arousal during reward anticipation with pupillometry in patients with major depressive disorder: replication and correlations with anhedonia. Sci Rep. 2024;14:344; https://doi.org/10.1038/s41598-023-48792-0
  2. Hall CA, Chilcott RP. Eyeing up the future of the pupillary light reflex in neurodiagnostics. Diagnostics. 2018;8.
  3. Mestanikova A, Ondrejka I, M. Mestanik M, et al. Pupillary light reflex is altered in adolescent depression. Physiol Res. 2017;66:S277–S284.
  4. Laurenzo SA, Kardon R, Ledoltr J, et al. Pupillary response abnormalities in depressive disorders. Psychiat Res. 2016;246:492–499.
  5. Wang J, Fan Y, Zhao, X, Chen N. Pupillometry in Chinese female patients with depression: A pilot study. Int J Environ Res Public Health. 2014;11:2236–2243.
  6. Sekaninova N, Ondrejka I, Bona Olexova L, et al. Oculometric behavior assessed by pupil response is altered in adolescent depression. Physiol Res. 2019;68:S325–S338.
Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.